ROZLYTREK (entrectinib) capsules, for oral use Initial U.S. Approval: 2019

Category: .

ROZLYTREK (entrectinib) capsules, for oral use Initial U.S. Approval: 2019

INDICATIONS AND USAGE
ROZLYTREK is a kinase inhibitor indicated for the treatment of:
• Adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive.
• Adult and pediatric patients 12 years of age and older with solid tumors.
This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.
DOSAGE FORMS & STRENGTHS
Capsules: 100 mg and 200 mg
Manufactured By: Genentech
Prescribing Information URL: Click Here

Access to ROZLYTREK (entrectinib) capsules: Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from Medvitaz Pharma Solutions.

Entrectinib, sold under the brand name Rozlytrek, is an anti-cancer medication used to treat ROS1-positive non-small cell lung cancer and NTRK fusion-positive solid tumors. It is a selective tyrosine kinase inhibitor (TKI), of the tropomyosin receptor kinases (TRK) A, B and C, C-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK).
It was approved for medical use in the United States in August 2019, in Australia in May 2020, and in the European Union in July 2020.

Reviews

There are no reviews yet.

Add a review

neeraj
Neeraj Nagpal

Head of Operations

 The profound knowledge of more than 20 years in sales and marketing sector, he has been working dedicatedly and contributing to pharmaceuticals industry. He handles all operations over the country.

Contact Our Team

Contact us and we will reply as soon as possible!

    need help?

     MEDVITAZ is an initiative for helping end-users directly to get the right medicines and right medical treatments from the right source.